Health Care/Hospital

MediThinQ Marks Milestone as First Asian Startup to Globally Launch XR Surgical Displays, Securing Key Partnerships and Multimillion-Dollar Investment

SINGAPORE, Feb. 20, 2024 /PRNewswire/ -- MediThinQ, a pioneering Korean startup specialising in extended reality (XR) wearable displays for surgery, is making waves as the first Asian startup to globally launch XR surgical displays. The company has successfully secured significant deals with indu...

2024-02-20 14:00 1407

Mount Alvernia Hospital Elevates Holistic Healthcare with OutSystems

Using the low-code platform, the hospital's in-house developers saved half the time it typically takes to develop applications for staff, patients and visitors. SINGAPORE, Feb. 20, 2024 /PRNewswire/ -- Mount Alvernia Hospital has partnered with OutSystems, a global leader in high-performance low...

2024-02-20 14:00 1748

Ciracle Cosmeceutical Brand to Host " Pore Control Blackhead Off Sheet" Experience Influencer Recruitment Event

SEOUL, South Korea, Feb. 19, 2024 /PRNewswire/ -- Ciracle, a cosmeceutical brand dedicated to pursuing skin health, will be hosting an influencer recruitment eventto experience the "Pore Control Blackhead Off Sheet" and other Ciracle products on its SNS platforms starting aroundthis April.

2024-02-20 13:28 1323

Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA

ROCKVILLIE, MD. and SUZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major di...

2024-02-20 08:22 2575

HKUST Neuroscientists Develop Highly Accurate Universal Diagnostic Blood Test for Alzheimer's Disease and Mild Cognitive Impairment

At a glance: * Remarkably high accuracy rate – over 96% for AD and 87% for MCI; * Applicable across diverse ethnic populations, including Chinese and European; * Enables early detection of AD and subsequent progression; * Captures multiple AD-associated biological pathways; * A game-chan...

2024-02-19 20:18 1664

Neurophth Announces Completion of Patient Enrollment for Opvika® Phase I/II Clinical Trial in the U.S.

WUHAN, China and SAN DIEGO, Feb. 19, 2024 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") announced today thatthe last patient has been enrolled in Phase I/II clinical trial of Opvika® (Esonadogene Imvoparvovec) for the treatment of Leber hereditary optic neuropathy caused byND4 mutati...

2024-02-19 19:30 1162

SIBIONICS Announced to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

The company will be hosting an influencer meeting during the conference LOS ANGELES, Feb. 19, 2024 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring (CGM) System brand, announced the company will be exhibiting at the International Fair of New Technologies in Diab...

2024-02-19 10:55 1640

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis

SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a biotechnology company dedicated to developing and commercializing transformative pharmaceutical, and surgical products that address critical unmet medical needs in ophthalmology, today announced that the Singapore Health ...

2024-02-19 09:00 3089

Everest Medicines Announces Termination of Collaboration Agreements with Providence

-Everest will continue to develop self-discovered products utilizing the mRNA platform- SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative...

2024-02-19 08:20 1588

SwiftMR™, Game-Changing AI-Powered MRI Solution Gears Up in ANZ Market: AIRS Medical Forges Strategic Partnership with ParagonCare

SEOUL, South Korea, Feb. 19, 2024 /PRNewswire/ -- AIRS Medical Inc., a leading provider of AI-powered healthcare solutions, has announced a strategic partnership agreement with ParagonCare Limited(ASX: PGC), a premier provider of healthcare technology, devices, software, and consumables inAustral...

2024-02-19 06:00 1833

Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor

BEIJING and SHANGHAI and BOSTON, Feb. 18, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received approval of registrational phase III clinical trial of the combination therapy between its novel KRAS G12C inhib...

2024-02-18 20:50 1811

China Medical University Hospital (CMUH) in Taiwan Upgrades Smart Healthcare with Gen AI

Establishing a comprehensive "AI-assisted Physician" using generative AI from Google Cloud, including MedLM TAICHUNG, Feb. 17, 2024 /PRNewswire/ -- China Medical University Hospital (CMUH) inTaiwan announced its collaboration with Google Cloud in mid-December 2023. Using Google Cloud's generativ...

2024-02-17 21:30 2095

New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy Across Diverse Tumors - published in the JITC

 - A new study published in the Journal for ImmunoTherapy of Cancer (JITC) shows that Lunit's AI-powered biomarker "Lunit SCOPE IO" can predict favorable outcomes of Inflamed Immune Phenotype patients treated with Immune Checkpoint Inhibitor across multiple cancer types SEOUL, South Korea, Feb. ...

2024-02-16 22:03 2305

IFPA Releases an Innovative Psoriatic Care Roadmap and Action Playbook

STOCKHOLM, Feb. 16, 2024 /PRNewswire/ -- IFPA Forum Asia 2023, held in Singapore , brought together a diverse group of stakeholders, including patient advocates, their associations, family members, policymakers, healthcare professionals, and the private sector. Held inSingapore, the forum served a...

2024-02-16 17:00 2870

4 WAYS THE BEEM BY START UP MUDO LABS ON KICKSTARTER WILL REVOLUTIONIZE THE WAY YOU MASTER YOUR MOOD

The pocket-sized device lets you enhance a given mood through acupressure and aromachology SINGAPORE, Feb. 16, 2024 /PRNewswire/ -- Here's a reality check: stress levels in the workplace have reached an all-time high. According to the Global Workplace 2021 Report, 43 percent of respondents in ov...

2024-02-16 16:12 657

Planetree's Person-Centered Care Certification Standards Achieve International Recognition for Quality

DERBY, Conn., Feb. 15, 2024 /PRNewswire/ -- Planetree's Person-Centered Care Certification® standards have been recognized by the International Society for Quality in Health Care's External Evaluation Association (ISQua EEA). This marks the first time a set of quality standards for person-centere...

2024-02-15 23:00 1533

Kim Byoung Joon LEDAS Varicose Vein Clinic Becomes the First Organization to be Accredited under GHA Standards for Medical Travel 5.0

PALM BEACH GARDENS, Fla., Feb. 15, 2024 /PRNewswire/ -- In a significant achievement that firmly underscores its commitment to the highest standards of healthcare, Kim Byoung Joon LEDAS Varicose Vein Clinic ( https://www.kbjledas.com/) in Busan, South Korea, has been awarded the distinguished Acc...

2024-02-15 19:00 1684

Pierre Fabre Laboratories and the EspeRare Foundation to be honored with the EURORDIS Company Award for Patient Engagement 2024, in their approach to co-developing a treatment for XLHED.

CASTRES, France and GENEVA, Feb. 15, 2024 /PRNewswire/ -- On February 20, International Ectodermal Dysplasias Awareness Day, Pierre Fabre Laboratories and the EspeRare Foundation will receive the EURORDIS Company Award for Patient Engagement 2024, at the EURORDIS Black Pearl Award Ceremony to be ...

2024-02-15 17:05 1762

Pharus Diagnostics Signs Worldwide Exclusive License Agreement with City of Hope for Novel Biomarkers to Be Used in Liquid Biopsy Screening for Early Pancreatic Cancer Diagnosis

LOS ANGELES, Feb. 15, 2024 /PRNewswire/ -- Pharus Diagnostics ("PharusDx") today announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic ductal adenocarcinoma (PDAC). This license...

2024-02-15 16:05 1735

iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology

▶ Robot Bacteriophage against microbiome associated with colorectal cancer ▶ Bacteriophage Improvement Platform technology with a broad antimicrobial activity ▶ Proprietary Technology incorporating CRISPR/Cas Technology BOSTON, Feb. 14, 2024 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.i...

2024-02-15 11:37 1326
1 ... 34353637383940 ... 809